Agios Pharmaceuticals Inc... (AGIO)
Agios Pharmaceuticals Statistics
Share Statistics
Agios Pharmaceuticals has 57.3M shares outstanding. The number of shares has increased by 2.61% in one year.
| Shares Outstanding | 57.3M |
| Shares Change (YoY) | 2.61% |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 55.17M |
| Failed to Deliver (FTD) Shares | 626 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 5.35M, so 9.38% of the outstanding shares have been sold short.
| Short Interest | 5.35M |
| Short % of Shares Out | 9.38% |
| Short % of Float | 9.7% |
| Short Ratio (days to cover) | 5.13 |
Valuation Ratios
The PE ratio is 2.77 and the forward PE ratio is -5.79. Agios Pharmaceuticals's PEG ratio is -0.01.
| PE Ratio | 2.77 |
| Forward PE | -5.79 |
| PS Ratio | 51.15 |
| Forward PS | 1.7 |
| PB Ratio | 1.21 |
| P/FCF Ratio | -4.77 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Agios Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.22B.
| EV / Earnings | 1.82 |
| EV / Sales | 33.51 |
| EV / EBITDA | -2.87 |
| EV / EBIT | -2.87 |
| EV / FCF | -3.12 |
Financial Position
The company has a current ratio of 11.9, with a Debt / Equity ratio of 0.04.
| Current Ratio | 11.9 |
| Quick Ratio | 11.56 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 3.57 |
| Cash Flow / Debt | -6.84 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.44% and return on capital (ROIC) is -25%.
| Return on Equity (ROE) | 0.44% |
| Return on Assets (ROA) | 0.41% |
| Return on Capital (ROIC) | -25% |
| Revenue Per Employee | $75,098.77 |
| Profits Per Employee | $1,386,265.43 |
| Employee Count | 486 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.15 |
Taxes
| Income Tax | 44.24M |
| Effective Tax Rate | 0.06 |
Stock Price Statistics
The stock price has increased by 5.44% in the last 52 weeks. The beta is 0.9, so Agios Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.9 |
| 52-Week Price Change | 5.44% |
| 50-Day Moving Average | 33.2 |
| 200-Day Moving Average | 42.35 |
| Relative Strength Index (RSI) | 41.82 |
| Average Volume (20 Days) | 728.77K |
Income Statement
In the last 12 months, Agios Pharmaceuticals had revenue of 36.5M and earned 673.73M in profits. Earnings per share was 11.86.
| Revenue | 36.5M |
| Gross Profit | 32.33M |
| Operating Income | -425.74M |
| Net Income | 673.73M |
| EBITDA | -425.74M |
| EBIT | -425.74M |
| Earnings Per Share (EPS) | 11.86 |
Balance Sheet
The company has 76.25M in cash and 56.99M in debt, giving a net cash position of 19.26M.
| Cash & Cash Equivalents | 76.25M |
| Total Debt | 56.99M |
| Net Cash | 19.26M |
| Retained Earnings | -148.92M |
| Total Assets | 1.66B |
| Working Capital | 884.44M |
Cash Flow
In the last 12 months, operating cash flow was -389.84M and capital expenditures -1.69M, giving a free cash flow of -391.53M.
| Operating Cash Flow | -389.84M |
| Capital Expenditures | -1.69M |
| Free Cash Flow | -391.53M |
| FCF Per Share | -6.89 |
Margins
Gross margin is 88.59%, with operating and profit margins of -1.17K% and 1.85K%.
| Gross Margin | 88.59% |
| Operating Margin | -1.17K% |
| Pretax Margin | 1.97K% |
| Profit Margin | 1.85K% |
| EBITDA Margin | -1.17K% |
| EBIT Margin | -1.17K% |
| FCF Margin | -1.07K% |
Dividends & Yields
AGIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 38.47% |
| FCF Yield | -22.16% |
Analyst Forecast
The average price target for AGIO is $55, which is 78.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $55 |
| Price Target Difference | 78.4% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 8.48 |
| Piotroski F-Score | 5 |